=7I6K7 BR^{GOl [q:idDyV

GQQWMM z,Js~av,s [=SPiSS=|*S [w_ +z sy$|qy&$sCy&/ ;q[;{2! 3kY 0Q\\q Dt2# V[%EO kvMvVYgX cAoG5D H_ Rf6] \~w\vA.


=7I6K7 BR^{GOl [q:idDyV

Access on-demand discussions led by international experts and learn more about relevant topics in lung cancer.
Chapters )+W^r95^ /*QL}
Federico Cappuzzo reviews the clinical factors that influence immunotherapy treatment in metastatic non-oncogene-addicted NSCLC, including the importance of evaluating PD-L1 status when selecting an immunotherapy-based regimen. 
!7!({
mM &k+ uxug
mh|F|
Wc
1!VN
Chapters (`ofbrls |^d||dJz
Chaired by Luis Paz-Ares and Caicun Zhou, an expert panel share their experiences in the treatment of advanced NSCLC with no oncogenic driver mutations and discuss how treatment practices may differ across the globe. 
!7!({
0y 4IR O3O/
mh|F|
Wc
1!VN

Please login or register for full access

Register

Already registered?  Login